Moderate

Shrinking lung syndrome

Rare SLE respiratory complication · Rheumatology
Physician-written · Verified by three sets of doctors · Reviewed November 2026

Bedside summary

A rare pulmonary complication of SLE characterised by unexplained dyspnoea, pleuritic pain and a restrictive defect with small lung volumes but no parenchymal disease, thought to reflect diaphragmatic dysfunction. Diagnosis is one of exclusion once ILD, PE and infection are ruled out.

Red flags

  • Rapidly progressive breathlessness (reconsider PE/ILD)
  • Hypoxaemia at rest
  • Orthopnoea suggesting significant diaphragm weakness
  • Signs of pulmonary hypertension
  • Fever suggesting infection

Assessment

Differential diagnosis

  • Lupus interstitial lung disease
  • Pulmonary embolism
  • Pleural effusion / serositis
  • Diaphragmatic palsy (other cause)
  • Pulmonary hypertension
  • Infective pneumonia

Investigations

  • Chest radiograph (small lung volumes, raised hemidiaphragms, basal atelectasis)
  • Pulmonary function tests (restrictive pattern, reduced lung volumes, preserved/normal transfer coefficient)
  • High-resolution CT chest (absence of significant parenchymal disease)
  • Diaphragmatic ultrasound / sniff test for diaphragm function
  • CTPA to exclude pulmonary embolism
  • SLE serology (ANA, anti-dsDNA, complement)

Management

  • Confirm restrictive physiology with small volumes and no parenchymal cause on HRCT
  • Exclude pulmonary embolism, infection and significant effusion
  • Assess diaphragmatic function
  • Optimise SLE disease control
  • Start corticosteroid as first-line therapy
  • Add a steroid-sparing immunosuppressant if inadequate response or to allow steroid taper
  • Consider beta-agonist / theophylline and physiotherapy for diaphragmatic support in selected cases
  • Monitor symptoms and serial lung function

Drugs & doses

Prednisolone — 0.5-1 mg/kg/day PO with gradual taper
Azathioprine — 1.5-2.5 mg/kg/day PO (check TPMT first)
Mycophenolate mofetil — 1 g PO BD if azathioprine unsuitable
Rituximab — 1 g IV days 1 and 15 for refractory disease
Hydroxychloroquine — 200-400 mg PO OD (max 5 mg/kg/day) for background lupus control

Disposition

Outpatient rheumatology/respiratory management with steroids; admit only for significant hypoxaemia or diagnostic uncertainty.

Complications & pitfalls

  • Chronic dyspnoea and reduced exercise tolerance
  • Respiratory muscle deconditioning
  • Recurrent atelectasis
  • Steroid-related adverse effects
  • Overlap with other lupus lung disease

Exam pearls

  • Think of it when an SLE patient has dyspnoea with a restrictive defect but a clear CT parenchyma
  • Preserved transfer coefficient (KCO) with reduced volumes points away from ILD
  • Generally responds well to corticosteroids
  • Diaphragmatic ultrasound is a useful non-invasive confirmatory test

Disclaimer: Educational decision support for qualified clinicians and students — not a substitute for clinical judgement, local protocols or a full drug reference. Confirm every dose and contraindication against your formulary before prescribing.